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Abbreviations 
  
FBC Full blood count 
Hb Haemoglobin 
HbF Foetal haemoglobin 
MTD Maximum tolerated dose 
SCA Sickle cell anaemia 
TCD Transcranial Doppler 
VDJ Variable diversity joining 
Abstract:  
Introduction  
Despite the demonstrated efficacy of hydroxyurea therapy, children with sickle cell anaemia in the 
United Kingdom (UK) are preferentially managed with supportive care or transfusion.  Hydroxyurea 
is reserved for children with severe disease phenotype.  This is in contrast to North America and other 
countries where hydroxyurea is widely used for children of all clinical phenotypes.  The conservative 
UK practice may in part be due to concerns about toxicity, in particular marrow suppression with high 
doses, and growth in children.  
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Methods and Results 
We monitored 37 paediatric patients with sickle cell anaemia who were treated with hydroxyurea at a 
single UK treatment centre.  Therapy was well tolerated and mild transient cytopenias were the only 
toxicity observed.  Comparative analysis of patients receiving ≥26mg/kg/day versus <26 mg/kg/day 
demonstrates increasing dose has a significant positive effect on foetal haemoglobin (29.2% v 20.4%, 
p=0.0151), mean cell volume (94.4 v 86.5, p=0.0183) and reticulocyte count (99.66 x109/L v 
164.3x109/L, p=0.0059).  Marrow suppression was not a clinical problem with high dose treatment, 
haemoglobin 92.25 g/L v 91.81 g/L (ns), neutrophil count 3.3 x109/L v 4.8 x109/L (ns) and platelet 
count 232.4 x109/L v 302.2 x109/L (ns).  Normal growth rates were maintained in all children.  Good 
adherence to therapy was a significant factor in reducing hospitalisations 
Conclusion 
This study demonstrates the effectiveness and safety in practice of high dose hydroxyurea as a disease 
modifying therapy which we advocate for all children with sickle cell anaemia.     
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Introduction  1 
In children with sickle cell anaemia (SCA), hydroxyurea therapy is effective at elevating foetal 2 
haemoglobin (HbF) and reducing the frequency of painful sickle crises[1-3].  Despite the demonstrated 3 
efficacy of hydroxyurea therapy, children with SCA are preferentially managed with supportive care or 4 
transfusion at United Kingdom (UK) treatment centres.  Current UK clinical guidance is supportive 5 
care and prophylactic antibiotics for all children, and transfusion in instances of acute and chronic 6 
complications such as acute anaemia, acute chest syndrome, acute neurological deficit, stroke 7 
prevention and organ failure.  Hydroxyurea is restricted to those with severe phenotype.  Current 8 
guidelines recommend it is considered only in patients who experience recurrent episodes of acute pain 9 
(more than 3 hospitalisations in the previous 12 months or symptomatic in the community) or who have 10 
experienced two or more episodes of acute chest syndrome[4].  Referral to a specialist centre is required 11 
for hydroxyurea commencement and it is recommended that the patient and parents or carers have two 12 
separate documented discussions with treating clinicians, to include side effects such as subfertility, 13 
cytopenias and the possible risk of leukaemia or other malignancies[4].  The effect of such guidance is 14 
that few children with SCA in the UK benefit from hydroxyurea therapy.  Currently 1.9% of UK patients 15 
with SCA <5 years of age receive hydroxyurea, and 11.3% of 5-17 year old UK SCA patients receive 16 
hydroxyurea[5].                17 
Reluctance to incorporate hydroxyurea into first line treatment in the UK relates in part to concerns 18 
over long term safety and negative effects on growth, combined with a lack of awareness of potential 19 
treatment benefits.  Since publication of the current UK Standards and Guidance for Clinical Care 20 
(2010), much more evidence as to the safety and efficacy of hydroxyurea therapy has become 21 
available[2,6-10].  In the USA, it is now recommended that all children with sickle cell anaemia be 22 
offered hydroxyurea therapy from 9 months of age[11].       23 
Concerns over potential negative effects on growth were addressed initially in the 1999 HUG-KIDS 24 
phase I/II trial.  Fifty two severely affected children aged 5-15 years were treated to maximum tolerated 25 
dose (MTD) with a median dose of 30mg/kg/day hydroxyurea for 1 year and no child experienced 26 
growth failure[12].  Following on from this, the HUSOFT extension study examined the effects of 27 
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longer term treatment (up to 6 years) on 21 very young children, and reported that females maintained 28 
average growth rates and males increased average growth rates during hydroxyurea therapy[13].   29 
Since hydroxyurea inactivates the enzyme ribonucleoside diphosphate reductase[14], it impairs both 30 
DNA replication and repair.  This gives rise to concerns as to its carcinogenic and teratogenic potential.  31 
So far, two follow up studies have investigated the risks and benefits of very long-term use in adults 32 
[15,16].  The Multicentre Study of Hydroxyurea in Sickle Cell Anaemia trial had a 17.5 year follow up 33 
and some participants had received greater than 15 years cumulative exposure.  This study found there 34 
was no increase in neoplasia by exposure to hydroxyurea[15].  Another single centre trial, where 131 35 
adults were followed for up to 17 years, also reported that no cases of carcinogenesis occurred[16].  36 
Importantly, both of these studies reported significantly improved survival in hydroxyurea treated 37 
patients[15,16].  More recently, investigators in the BABY-HUG phase III clinical trial sought to 38 
measure acquired genomic damage in infants, as a measure of carcinogenic potential.  Karyotype 39 
analysis (to investigate chromosome/chromatid breaks), illegitimate variable-diversity-joining (VDJ) 40 
recombination events and micronucleated reticulocytes were monitored and there were no differences 41 
between hydroxyurea and placebo treated patients[10]. 42 
Since the reporting of the BABY-HUG trial results, we have offered hydroxyurea as a first line 43 
treatment to all children over 9 months of age with SCA at this UK centre.  Here, we sought to review 44 
the benefits of hydroxyurea therapy in a UK paediatric cohort, and to determine the effect of dose 45 
escalation and adherence to therapy in terms of improvement in haematological parameters and hospital 46 
admissions.    47 
Methods  48 
All children over 9 months of age were offered hydroxyurea therapy and no selection for disease 49 
severity was made.  Baseline investigations were performed to confirm the absence of anaemia 50 
(haemoglobin (Hb) >50g/L), absence of cytopenias (neutrophils >1.0 x 109/L, platelets >100x109/L, 51 
reticulocytes >40x109/L) and absence of severe hepatic or renal impairment (estimated glomerular 52 
filtration rate >30mL/min/1.73m2).  Patients were not considered for hydroxyurea therapy if they had 53 
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known hypersensitivity to hydroxyurea, were pregnant, had active hepatitis, showed any signs of 54 
myelosuppression or were receiving anti-retroviral therapy.   55 
Treatment commenced at 15 mg/kg/day to be increased over the following 12 months to MTD or 35 56 
mg/kg/day, whichever was achieved first.  MTD was defined by haematological toxicity as the 57 
maximum dose where no myelosuppression was induced.  On commencement of therapy, full blood 58 
counts (FBC) were monitored fortnightly for the first 4 weeks and then at 4 weekly intervals.  Clinical 59 
assessment was made monthly and included frequency and severity of crises, complications of sickle 60 
cell disorders, compliance with treatment, adverse events, height and weight measurements and 61 
laboratory monitoring of hepatic and renal function, reticulocytes, FBC and haemoglobin 62 
electrophoresis.  Dose was increased by 5mg/kg/day every 8 weeks, provided that no marrow toxicity 63 
was observed (defined as neutrophil count <0.75 x109/L or platelet count <75 x109/L or reticulocyte 64 
count <40 x109/L).  FBCs were monitored fortnightly following dose increases for 4 weeks, and then 65 
at 4 weekly intervals.       66 
Results  67 
Ninety five percent of children and parents or carers offered hydroxyurea consented following 68 
discussion of current evidence in relation to side effects and benefits of treatment (n = 37).  Hydrea in 69 
500mg capsule or liquid formulation was prescribed.  The mean age at start of therapy in our patients 70 
was 7 years (range 1 – 15), 34 patients were HbSS, 2 were HbSβ0 thalassemia and 1 was HbSD.  The 71 
mean dose achieved in patients who had been on therapy for more than 6 months was 28.5 mg/kg/day.   72 
Significant improvements were recorded in haematological parameters post-hydroxyurea therapy; Hb 73 
increased to 92.0 g/L from 80.6 g/L, HbF increased to 26.35% from 9.90%, MCV increased to 91.06 74 
from 77.49, reticulocytes decreased to 127.6 x109/L from 335.4 x109/L and neutrophils decreased to 75 
3.95 x109/L from 6.37 x109/L (n=37; p<0.001 by paired t-test for each parameter; supplemental figure 76 
1 (S1)).  A significant reduction in platelets was also recorded in our patients (to 263.3 x109/L from 77 
352.4 x109/L; p=0.0007; supplemental figure 1 (S1)).     78 
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At the time of review, 16 patients were receiving <26 mg/kg/day hydroxyurea and 21 patients were 79 
receiving ≥26 mg/kg/day.  Comparative analysis of patients receiving <26 and ≥26 mg/kg/day indicated 80 
that dose had a significant effect on some parameters.  Hb levels were increased post-hydroxyurea 81 
therapy irrespective of dose achieved (Figure 1A).  Whereas HbF level, MCV and reticulocyte count 82 
were further improved in patients receiving ≥26 mg/kg/day (Figure 1B, 1C & 1D).  Neutrophil and 83 
platelet counts were only significantly reduced in patients receiving ≥26mg/kg/day (Figure 1E & 1F).  84 
Patient age versus dose achieved is shown in Figure 1G.     85 
Haemolysis was better controlled in patients receiving ≥26mg/kg/day.  Bilirubin and lactate 86 
dehydrogenase (LDH) were significantly lower in patients receiving ≥26 mg/kg/day (Figure 2A & 2B).  87 
Concurrent monitoring of alanine amino transferase (ALT) and aspartate amino transferase (AST) 88 
showed no evidence of liver toxicity in any patient, although AST was significantly reduced in patients 89 
receiving ≥26mg/kg/day (Figure 2C & 2D).  Serum creatinine and urea were monitored continuously 90 
and remained within age appropriate reference range for all patients.         91 
Adherence to therapy was reported by the patient and parent or carer at each clinic visit.  We identified 92 
10 patients with poor adherence to therapy based on patient/parent/carer admission and confirmed that 93 
they had not collected prescriptions regularly enough to maintain prescribed daily dosing.  Comparative 94 
analysis between these patients with poor adherence, and all other patients who were considered to have 95 
good adherence (based on patient/parent/carer reporting), indicates that improvement in haematological 96 
parameters is dependent on good adherence to therapy (Figure 3).  Hb and HbF levels were significantly 97 
higher in patients with good adherence (Figure 3A & 3B).  As would be expected, MCV was 98 
significantly higher with good adherence (Figure 3C), and reticulocyte and neutrophil counts were 99 
significantly lower (Figure 3D & 3E).  Adherence had no significant effect on platelet count (Figure 100 
3F) or haemolysis (Bilirubin/LDH; Figure 3G & 3H) however, both ALT and AST were significantly 101 
reduced with good adherence which may indicate beneficial effects on hepatic function (Figure 3I and 102 
3J).     103 
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Adherence to therapy also had a significant impact on the number of hospitalisations experienced by 104 
patients.  Twenty seven hospitalisations totalling 126 admission days were recorded for the 10 patients 105 
with poor adherence, compared to 9 hospitalisations totalling 49 admission days in the 27 patients with 106 
good adherence (p<0.0001 by χ2 test; 24 month follow up).  Height and weight were monitored 107 
continuously for all patients and growth rates were maintained in all children irrespective of dose 108 
achieved or adherence to therapy (Figure 4).     109 
Discussion  110 
Our data demonstrates the significant improvements in haematological parameters that can be achieved 111 
with hydroxyurea therapy in UK paediatric patients with SCA.  All children in this study had previously 112 
been managed at UK treatment centres with supportive care or transfusions.  Importantly, hydroxyurea 113 
resulted in significant improvements in Hb, HbF, MCV, reticulocyte and neutrophil count which were 114 
apparent within 6 months of therapy commencement.  Our data indicates that dose escalation is required 115 
to maximise beneficial effects, particularly in respect of HbF where patients receiving ≥26mg/kg/day 116 
achieved a median HbF level of 33.80%.  HbF may protect HbS from de-oxygenation and 117 
polymerisation through local oxygen buffering, and is considered a good indicator of clinical disease 118 
severity[17] .  Escalating dose to ≥26mg/kg/day exerted better control of haemolysis with increased Hb 119 
and deceased bilirubin, LDH and reticulocytes.  Our study also highlights the critical importance of 120 
good adherence to therapy, particularly in respect to hospitalisations and admission days.   121 
An increasing body of literature exists demonstrating the efficacy of hydroxyurea in SCA.  The most 122 
notable recent demonstration in paediatric patients is arguably the BABY-HUG multicentre randomised 123 
controlled trial[2].  Similar to the improvements seen here, the BABY-HUG investigators reported 124 
significant improvements in Hb, HbF, MCV, reticulocyte count and neutrophil count in hydroxyurea 125 
treated patients.  Further, the BABY-HUG investigators reported improvements in renal function and 126 
cerebral artery blood flow based on transcranial Doppler (TCD) velocity.  Clinical events were also 127 
improved, with significantly reduced incidences of pain, acute chest syndrome, hospitalisation, 128 
transfusion, dactylitis and gastroenteritis[2].   129 
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The UK paediatric patient cohort in this study benefited from hydroxyurea therapy as expected based 130 
on previous reports of hydroxyurea use in SCA[2,12,13,18].  As such we believe it is now time to 131 
address the barriers to therapy that exist within the UK.  No negative effects on growth were observed 132 
in this study and the only treatment related toxicities encountered were cytopenias, most frequently mild 133 
cytopenias which resolved without the need for dose reduction.   134 
We considered neutrophil count <0.75 x109/L, or platelet count <75 x109/L, or reticulocyte count <40 135 
x109/L clinically significant toxicities.  Nine of the 37 children treated experienced significant 136 
cytopenia, totalling 22 separate episodes.  Three children experienced a single episode (2 137 
reticulocytopenia, 1 thrombocytopenia) while being clinically well.  Laboratory monitoring was 138 
increased to weekly and counts recovered within 2 weeks (thrombocytopenia) and 6 weeks 139 
(reticulocytopenia) without the need for dose adjustment.  One child experienced two episodes of 140 
reticulocytopenia 8 months apart while being clinically well, and 1 child experienced two episodes of 141 
thrombocytopenia 15 months apart while being clinically well.  Both children were managed with 142 
increased laboratory monitoring and counts recovered within 2 weeks (thrombocytopenia) or 3 weeks 143 
(reticulocytopenia) without the need for dose adjustment.  Three children experienced cytopenias 144 
following dose increase or alongside falling haemoglobin or neutrophil count, which required dose 145 
adjustment (6 thrombocytopenia and 1 reticulocytopenia).  Hydroxyurea therapy was stopped and 146 
laboratory monitoring increased to weekly.  Hydroxyurea was re-commenced following recovery of 147 
counts, which occurred within 1 – 3 weeks.  Therapy was recommenced at the same dose for children 148 
receiving <20mg/kg/day or at a reduced dose for children receiving >20mg/kg/day.  One child with 149 
severe phenotype experienced 7 episodes of cytopenia over 21 months (4 neutropenia, 3 150 
reticulocytopenia).  Each cytopenia was managed with increased laboratory monitoring and resolved 151 
without the need for dose reduction.  We persisted with hydroxyurea therapy for this patient as 152 
significant improvement in clinical features were seen, including reduced crisis, return of conditional 153 
TCD to normal and increase in HbF from 7.0% to 32.7%.  In our experience, isolated cytopenias are 154 
best managed initially with increased laboratory monitoring (weekly) while maintaining dose in 155 
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clinically well children.  Dose reduction or therapy cessation should be considered when an isolated 156 
cytopenia is persistent or deteriorates, or if more than one haematological parameter is affected.        157 
While hydroxyurea therapy resulted in clinical improvement, in comparison to a supportive care 158 
approach, it also resulted in increased medication related burden on patients and families.  In this 159 
respect, when children are established on a stable dose it may be possible to reduce monitoring to 160 
bimonthly to counteract some of this additional burden[20].  Achieving accurate dosing in children 161 
prescribed 500mg capsules frequently required an ‘asymmetric’ daily dosing schedule to achieve a 162 
desired weekly intake, and this adds an additional layer of complexity to daily administration.  However, 163 
these issues were overcome in our patients and their families who were motivated by tangible treatment 164 
benefits such as improvements in laboratory values.               165 
Currently, the UK National Haemoglobinopathy Registry shows only 9.5% of all UK patients with SCA 166 
<18 years of age receive hydroxyurea therapy[5].  In the absence of substantive evidence to contradict 167 
safety, we advocate the use of hydroxyurea as a disease modifying therapy for all UK children with 168 
SCA.  Future UK clinical guidelines should place more focus on achievable benefits with hydroxyurea, 169 
and broaden the application to many more children.    170 
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Legends 235 
Figure 1.  Hydroxyurea (HU) improves haematological parameters.  Increased Hb (A), increased 236 
HbF (B), increased MCV (C) and decreased reticulocytes (D) were observed post-treatment irrespective 237 
of dose achieved, although treating with ≥26mg/kg further improved HbF, MCV and reticulocyte count.  238 
Treatment with ≥26mg/kg also resulted in decreased neutrophils (E) and platelets (F).  Lines indicate 239 
mean ± SD, statistics by paired t-test for pre/post treatment comparison and by t-test for dose 240 
comparison.  Dose achieved did not correlate with patient age (G), dotted line indicates 26mg/kg 241 
threshold used for dose comparison.   242 
Figure 2.  Hydroxyurea (HU) improves control of haemolysis.  Bilirubin (A) and lactate 243 
dehydrogenase (LDH; B) were reduced in children receiving ≥26mg/kg hydroxyurea.  Alanine amino 244 
transferase (ALT) remained stable irrespective of dose (C) and aspartate amino transferase (AST) was 245 
reduced in children receiving ≥26mg/kg (D).  Lines indicate mean ± SD, statistics by paired t-test for 246 
pre/post treatment comparison and by t-test for dose comparison.  Grey shading indicates normal 247 
reference range for each parameter measured.     248 
Figure 3.  Effects of good adherence to therapy.  Good adherence to therapy had a significant effect 249 
on Hb (A), HbF (B), MCV (C), reticulocyte count (D) and neutrophil count (E) but not on platelet count 250 
(F).  No significant effects were recorded in bilirubin (G) or LDH (H) but ALT (I) and AST (J) were 251 
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significantly reduced by good adherence to therapy.  Lines indicate mean ± SD, statistics by t-test, grey 252 
shading represents normal reference range for each parameter (G-J).     253 
Figure 4.  Growth rates in children following hydroxyurea therapy.  Height (A) and weight (B) 254 
were maintained in children treated with hydroxyurea.  Arrow indicates commencement of hydroxyurea 255 
therapy.  Data shown is height for age (A) and weight for age (B) z-score calculated using CDC growth 256 
chart[19] 257 
Supplemental Figure 1.  Hydroxyurea (HU) improves haematological parameters.  Significant 258 
improvements in haemoglobin (Hb), foetal haemoglobin (HbF), mean cell volume (MCV), reticulocyte 259 
count and neutrophil count were recorded post-HU therapy in UK paediatric patients with sickle cell 260 
anaemia.  Platelets were also significantly reduced post-HU therapy.    261 
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 262 
Figure 1 Hydroxyurea (HU) improves haematological parameters.  Increased Hb (A), increased HbF (B), increased MCV (C) and decreased reticulocytes (D) were observed post-treatment 263 
irrespective of dose achieved, although treating with ≥26mg/kg further improved HbF, MCV and reticulocyte count.  Treatment with ≥26mg/kg also resulted in decreased neutrophils (E) and 264 
platelets (F).  Lines indicate mean ± SD, statistics by paired t-test for pre/post treatment comparison and by t-test for dose comparison.  Dose achieved did not correlate with patient age (G), 265 
dotted line indicates 26mg/kg threshold used for dose comparison. 266 
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 267 
Figure 2 Hydroxyurea (HU) improves control of haemolysis.  Bilirubin (A) and lactate dehydrogenase (LDH; B) were reduced in children receiving ≥26mg/kg hydroxyurea.  Alanine amino 268 
transferase (ALT) remained stable irrespective of dose (C) and aspartate amino transferase (AST) was reduced in children receiving ≥26mg/kg (D).  Lines indicate mean ± SD, statistics by 269 
paired t-test for pre/post treatment comparison and by t-test for dose comparison.  Grey shading indicates normal reference range for each parameter measured 270 
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 271 
Figure 3 Effects of good adherence to therapy.  Good adherence to therapy had a significant effect on Hb (A), HbF (B), MCV 272 
(C), reticulocyte count (D) and neutrophil count (E) but not on platelet count (F).  No significant effects were recorded in 273 
bilirubin (G) or LDH (H) but ALT (I) and AST (J) were significantly reduced by good adherence to therapy.  Lines indicate 274 
mean ± SD, statistics by t-test, grey shading represents normal reference range for each parameter (G-J). 275 
 276 
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 277 
Figure 4 Growth rates in children following hydroxyurea therapy.  Height (A) and weight (B) were maintained in children treated with hydroxyurea.  Arrow indicates commencement of 278 
hydroxyurea therapy.  Data shown is height for age (A) and weight for age (B) z-score calculated using CDC growth chart[19] 279 
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